MaineHealth

MaineHealth Knowledge Connection

Costas T. Lambrew Research Retreat 2022

Costas T. Lambrew Research Retreat

4-25-2022

Demographic Factors Contributing to NAS Treatment

Meg Curran Maine Medical Center

Emma Freeman Maine Medical Center

Follow this and additional works at: https://knowledgeconnection.mainehealth.org/lambrew-retreat-2022



Part of the Pediatrics Commons

Recommended Citation

Curran, Meg and Freeman, Emma, "Demographic Factors Contributing to NAS Treatment" (2022). Costas T. Lambrew Research Retreat 2022. 19.

https://knowledgeconnection.mainehealth.org/lambrew-retreat-2022/19

This Book is brought to you for free and open access by the Costas T. Lambrew Research Retreat at MaineHealth Knowledge Connection. It has been accepted for inclusion in Costas T. Lambrew Research Retreat 2022 by an authorized administrator of MaineHealth Knowledge Connection.



Infants that were formula fed, had unpartnered parents, birthing parents who used illicit substances, and multiple medication exposures were more likely to be treated for NAS



Demographic Factors Contributing to NAS Treatment

Emma Freeman, M3¹, Meg Curran, MD²

¹Tufts University School of Medicine Maine Track Program, Portland, ME; ²Maine Medical Center, Department of Family Medicine, Portland, ME

Background


- Neonatal abstinence syndrome (NAS) is characterized by symptoms of withdrawal that occur due to the cessation of exposure to a substance used by the birthing parent during pregnancy.
- The Finnegan score is a commonly used assessment tool used to quantify NAS and set a threshold above which infants should be considered for NAS treatment.
- The NAS rate in Maine in 2018 was 28.3 per 1,000 hospital births, compared to a national incidence rate of 7 per 1,000 in 2016 (NIH, 2020).
- In 2017, the cost of hospital stay for a neonate with NAS was **eight** times for the cost of an average newborn hospital stay (CDC, 2021).
- Understanding what factors are shared amongst infants treated for NAS can facilitate future treatment decisions.

Infants by Finnegan score

Status	Treated, n = 202	Untreated, n = 273
Above threshold, n = 292	191	101
Below threshold, n = 183	11	172

Methods

- Data analysis was performed of 480 total neonates born at MMC between 2013 and 2016
- Neonates were compared that were treated for NAS who fell above and below the threshold to treat based on their Finnegan score
- Demographics were compared amongst neonates in the four groups
 - Variables: marital status, substance used by birthing parent, feeding method, gestational age, and birthweight



Demographic factors



Results

Factors that are significantly different amongst neonates treated versus untreated for NAS (p < 0.05)

Demographic factor	Total	Treated	Untreated
Marital Status** Single Partnered	209	102	107
	269	100	169
Substance Illicit vs Prescription* Illicit Prescription Multiple medications** Opioids alone Opioids with other substances	10842333375	561747183	5224926192
Feeding Status** Breastmilk Formula Breastmilk & Formula	50	3	47
	169	89	80
	257	109	148
Gestational Age < 37 weeks ≥ 37 weeks Average age	56	30	26
	423	174	250
	38w 5d	38w 4d	38w 5d
Birthweight < 2500 g 2500 - 4000 g > 4000 g Average weight (g)	82	41	41
	376	154	222
	20	7	13
	3083.4	3045.6	3111.0

*Significant amongst all infants
**Significant amongst infants above the threshold to treat

Discussion

- For all infants, those that were formula fed, had unpartnered parents, birthing parents who used illicit substances, and multiple medication exposures were more likely to be treated for NAS regardless of Finnegan score.
- For infants above the treatment threshold, those that were formula fed, had unpartnered parents, and multiple medication exposures were more likely to be treated for NAS regardless of Finnegan score.
- The identification of these demographic factors will help us to identify infants that may be more or less likely to necessitate NAS treatment.